Meridian Bioscience Total Assets 2006-2018 | VIVO

Meridian Bioscience total assets from 2006 to 2018. Total assets can be defined as the sum of all assets on a company's balance sheet.
Meridian Bioscience Annual Total Assets
(Millions of US $)
2018 $251
2017 $250
2016 $252
2015 $183
2014 $177
2013 $177
2012 $161
2011 $155
2010 $155
2009 $156
2008 $146
2007 $133
2006 $121
2005 $111
Meridian Bioscience Quarterly Total Assets
(Millions of US $)
Q1 2018 $250
Q4 2018 $251
Q3 2018 $254
Q2 2018 $255
Q1 2017 $252
Q4 2017 $250
Q3 2017 $245
Q2 2017 $252
Q1 2016 $250
Q4 2016 $252
Q3 2016 $255
Q2 2016 $258
Q1 2015 $186
Q4 2015 $183
Q3 2015 $179
Q2 2015 $178
Q1 2014 $177
Q4 2014 $177
Q3 2014 $179
Q2 2014 $178
Q1 2013 $175
Q4 2013 $177
Q3 2013 $171
Q2 2013 $166
Q1 2012 $157
Q4 2012 $161
Q3 2012 $159
Q2 2012 $158
Q1 2011 $155
Q4 2011 $155
Q3 2011 $158
Q2 2011 $157
Q1 2010 $156
Q4 2010 $155
Q3 2010 $149
Q2 2010 $152
Q1 2009 $155
Q4 2009 $156
Q3 2009 $148
Q2 2009 $146
Q1 2008 $146
Q4 2008 $146
Q3 2008 $141
Q2 2008 $141
Q1 2007 $135
Q4 2007 $133
Q3 2007 $126
Q2 2007 $122
Q1 2006 $122
Q4 2006 $121
Q3 2006 $115
Q2 2006 $110
Q1 2005 $111
Q4 2005 $111
Q3 2005 $81
Q2 2005 $80
Sector Industry Market Cap Revenue
Medical Medical Products Manufacturing $0.531B $0.214B
Meridian Bioscience, Inc. is a fully integrated life science company that manufactures, markets and distributes a broad range of innovative diagnostic test kits, purified reagents and biopharmaceutical enabling technologies that help deliver answers. Its products provide accuracy, simplicity and speed for the early diagnosis and treatment of common medical conditions, such as C. difficile, H. pylori, foodborne diseases and respiratory infections. In addition, the company develops and manufactures a variety of biological and non-biological materials used in proficiency testing programs. Meridian diagnostic products are used outside of the human body and require little or no special equipment. Meridian Bioscience designs their products to enhance the well-being of the patient-while reducing the total outcome costs of healthcare. Meridian has strong market positions in the areas of gastrointestinal infections, serology, parasitology and fungal disease diagnosis.
Stock Name Country Market Cap PE Ratio
Abbott Laboratories (ABT) United States $129.838B 25.32
Medtronic (MDT) Ireland $112.952B 16.51
Stryker (SYK) United States $67.256B 24.66
Boston Scientific (BSX) United States $48.820B 23.72
Baxter (BAX) United States $37.991B 24.37
Zimmer Biomet Holdings (ZBH) United States $24.550B 15.71
Smith & Nephew SNATS (SNN) United Kingdom $16.615B 0.00
Canopy Growth (CGC) Canada $14.912B 0.00
ResMed (RMD) United States $14.218B 26.96
Aurora Cannabis (ACB) Canada $9.118B 64.29
Bio-Rad Laboratories (BIO) United States $8.765B 50.28
Perrigo (PRGO) Ireland $6.633B 10.75
Hill-Rom Holdings (HRC) United States $6.374B 19.72
Insulet (PODD) United States $4.900B 1642.60
GW Pharmaceuticals (GWPH) United Kingdom $4.701B 0.00
ICU Medical (ICUI) United States $4.568B 28.29
Haemonetics (HAE) United States $4.189B 37.16
Hutchison China MediTech (HCM) China $4.046B 0.00
Agios Pharmaceuticals (AGIO) United States $3.268B 0.00
Neogen (NEOG) United States $2.958B 48.10
NuVasive (NUVA) United States $2.784B 24.18
Quidel (QDEL) United States $2.365B 21.17
National Vision Holdings (EYE) United States $2.220B 43.66
Aphria (APHA) $1.917B 0.00
Phibro Animal Health (PAHC) United States $1.349B 19.38
VAREX IMAGING (VREX) United States $1.222B 23.93
Cardiovascular Systems (CSII) United States $1.190B 854.00
AtriCure (ATRC) United States $1.049B 0.00
Lantheus Holdings (LNTH) United States $0.931B 25.16
Omeros (OMER) United States $0.908B 0.00
PetIQ (PETQ) United States $0.862B 24.67
MacroGenics (MGNX) United States $0.791B 0.00
Cerus (CERS) United States $0.787B 0.00
NanoString Technologies (NSTG) United States $0.737B 0.00
TG Therapeutics (TGTX) United States $0.689B 0.00
Evolus (EOLS) United States $0.681B 0.00
Eagle Pharmaceuticals (EGRX) United States $0.666B 22.66
OraSure Technologies (OSUR) United States $0.594B 25.86
Surmodics (SRDX) United States $0.546B 79.43
LeMaitre Vascular (LMAT) United States $0.536B 25.46
Quanterix (QTRX) United States $0.492B 0.00
Neptune Technologies & Bioresources Inc (NEPT) Canada $0.322B 0.00
Utah Medical Products (UTMD) United States $0.321B 20.88
Insys Therapeutics (INSY) United States $0.313B 0.00
BioLife Solutions (BLFS) United States $0.305B 125.85
Vapotherm (VAPO) United States $0.296B 0.00
Rockwell Medical (RMTI) United States $0.271B 0.00
Cytosorbents (CTSO) United States $0.219B 0.00
Owens & Minor (OMI) United States $0.213B 2.91
Zynex (ZYXI) United States $0.171B 18.31
Chimerix (CMRX) United States $0.133B 0.00
Bovie Medical (APYX) United States $0.131B 0.00
Fonar (FONR) United States $0.125B 6.68
Chembio Diagnostics (CEMI) United States $0.121B 0.00
Surface Oncology (SURF) United States $0.113B 0.00
Female Health (VERU) United States $0.088B 0.00
United-Guardian (UG) United States $0.088B 20.06
CAS Medical Systems (CASM) United States $0.072B 0.00
Neurotrope (NTRP) United States $0.071B 0.00
Trinity Biotech (TRIB) Ireland $0.071B 21.00
Oramed Pharmaceuticals (ORMP) United States $0.070B 0.00
ImmuCell (ICCC) United States $0.043B 0.00
Senestech (SNES) United States $0.034B 0.00
Valeritas Holdings (VLRX) United States $0.031B 0.00
Conatus Pharmaceuticals (CNAT) United States $0.025B 0.00
Capricor Therapeutics (CAPR) United States $0.018B 0.00
InVivo Therapeutics Holdings (NVIV) United States $0.014B 0.00
Cellectar Biosciences (CLRB) United States $0.012B 0.00
Akers Biosciences Inc (AKER) United States $0.010B 0.00
NeuroMetrix (NURO) United States $0.008B 13.71